CD3+T-lymphocyte infiltration is an independent prognostic factor for advanced nasopharyngeal carcinoma

Locally advanced nasopharyngeal carcinoma (LA-NPC) is a relatively rare disease in the west but more common in East Asia and areas of the Middle East like Saudi Arabia. Despite the advances in radiation therapy techniques, some patients relapse after treatment. In the coming era of cancer immunother...

Full description

Saved in:
Bibliographic Details
Published in:BMC cancer 2020-03, Vol.20 (1), p.240-13, Article 240
Main Authors: Al-Rajhi, Nasser, Soudy, Hussein, Ahmed, Shoaib A, Elhassan, Tusneem, Mohammed, Shamayel F, Khoja, Hatim A, Ghebeh, Hazem
Format: Article
Language:English
Subjects:
Abdomen
Analysis
Biomarkers
Cancer
Cancer immunotherapy
Cancer metastasis
Cancer treatment
Carcinoma
Care and treatment
CD3
CD3 antigen
CD8 antigen
Chemo-radiotherapy
Chemotherapy
Clinical trials
Diseases
Immune infiltrate
Immunotherapy
Infiltration
Lymphocytes
Lymphocytes T
Medical imaging
Metastases
Metastasis
Nasopharyngeal carcinoma
Patients
PD-L1 protein
Pembrolizumab
Platinum
Prognosis
Radiation (Physics)
Radiation therapy
Radiotherapy
Rare diseases
Statistical analysis
Throat cancer
Tumor-infiltrating lymphocytes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Locally advanced nasopharyngeal carcinoma (LA-NPC) is a relatively rare disease in the west but more common in East Asia and areas of the Middle East like Saudi Arabia. Despite the advances in radiation therapy techniques, some patients relapse after treatment. In the coming era of cancer immunotherapy, prognostic factors for LA-NPC need to be further defined using immune-relevant markers. Several markers are available; however, the most robust and accessible/affordable marker is not well-defined. Retrospectively, tumor-infiltrating lymphocytes (TIL), their subsets as well as tumoral PD-L1 expression were analyzed in tumor tissues from 63 LA-NPC patients treated with platinum-based concurrent chemo-radiotherapy (CCRT) in addition to 20 cases with metastatic (MET) disease. Immunostaining was done using a validated and fully automated system. Scoring was done by two independent pathologists and results were compared. There was no statistical difference between LA-NPC and MET disease in terms of CD3+, CD8+ TIL infiltration, or tumoral PD-L1 expression. In LA-NPC, low CD3+ TIL infiltration highly correlated with shorter disease-free survival (DFS, HR = 8.5, p = 
ISSN:1471-2407
1471-2407
DOI:10.1186/s12885-020-06757-w